3.14MMarket Cap-0.17P/E (TTM)
2.5500High2.3750Low13.13KVolume2.4500Open2.4500Pre Close32.23KTurnover1.45%Turnover RatioLossP/E (Static)1.27MShares9.250052wk High0.18P/B2.25MFloat Cap2.200052wk Low--Dividend TTM908.92KShs Float170.0000Historical High--Div YieldTTM7.14%Amplitude2.2000Historical Low2.4540Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Tuesday, 14th January at 8:02 am
-- Interim data from Cohort 4 expected Q1 2025 --
MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (...
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
No comment yet